APpEaLINg therapeutic target for obesity cardiomyopathy?

Journal of Molecular and Cellular Cardiology

Volumn 63, Issue , 2013, Pages 165-168

  Wende, Adam R ^a   Young, Martin E ^b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; APELIN; CALCIUM; GLUCOSE; INSULIN; LEPTIN; MICRORNA; NITROGEN DERIVATIVE; REACTIVE OXYGEN METABOLITE;

ATHEROSCLEROSIS; AUTOPHAGY; CALCIUM HOMEOSTASIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DYSLIPIDEMIA; EDITORIAL; ENDOPLASMIC RETICULUM; GENE DELETION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; HEART VENTRICLE HYPERTROPHY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPATHETIC TONE;

ANIMALS; CARDIOMYOPATHIES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; OBESITY;

EID: 84884795205     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.08.001     Document Type: Editorial

References (39)

1. Wende A.R., Symons J.D., Abel E.D. Mechanisms of lipotoxicity in the cardiovascular system. Curr Hypertens Rep 2012, 14:517-531.
2. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 2013, 127:e6-e245.
3. McGavock J.M., Victor R.G., Unger R.H., Szczepaniak L.S., American College of P, the American Physiological S Adiposity of the heart, revisited. Ann Intern Med 2006, 144:517-524.
4. Harmancey R., Wilson C.R., Taegtmeyer H. Adaptation and maladaptation of the heart in obesity. Hypertension 2008, 52:181-187.
5. Wong C., Marwick T.H. Obesity cardiomyopathy: diagnosis and therapeutic implications. Nat Clin Pract Cardiovasc Med 2007, 4:480-490.
6. Abel E.D., Litwin S.E., Sweeney G. Cardiac remodeling in obesity. Physiol Rev 2008, 88:389-419.
7. Wong C., Marwick T.H. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med 2007, 4:436-443.
8. Brindley D.N., Kok B.P., Kienesberger P.C., Lehner R., Dyck J.R. Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization. Am J Physiol Endocrinol Metab 2010, 298:E897-E908.
9. Waki H., Tontonoz P. Endocrine functions of adipose tissue. Annu Rev Pathol 2007, 2:31-56.
10. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
11. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005, 11:1096-1103.
12. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
13. Xu S., Tsao P.S., Yue P. Apelin and insulin resistance: another arrow for the quiver?. J Diabetes 2011, 3:225-231.
14. Kleinz M.J., Davenport A.P. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept 2004, 118:119-125.
15. Glassford A.J., Yue P., Sheikh A.Y., Chun H.J., Zarafshar S., Chan D.A., et al. HIF-1 regulates hypoxia- and insulin-induced expression of apelin in adipocytes. Am J Physiol Endocrinol Metab 2007, 293:E1590-E1596.
16. Kleinz M.J., Skepper J.N., Davenport A.P. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept 2005, 126:233-240.
17. Tatemoto K., Hosoya M., Habata Y., Fujii R., Kakegawa T., Zou M.X., et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998, 251:471-476.
18. Tatemoto K., Takayama K., Zou M.X., Kumaki I., Zhang W., Kumano K., et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 2001, 99:87-92.
19. Dray C., Knauf C., Daviaud D., Waget A., Boucher J., Buleon M., et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab 2008, 8:437-445.
20. Yue P., Jin H., Xu S., Aillaud M., Deng A.C., Azuma J., et al. Apelin decreases lipolysis via G(q), G(i), and AMPK-Dependent Mechanisms. Endocrinology 2011, 152:59-68.
21. Yue P., Jin H., Aillaud M., Deng A.C., Azuma J., Asagami T., et al. Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab 2010, 298:E59-E67.
22. Higuchi K., Masaki T., Gotoh K., Chiba S., Katsuragi I., Tanaka K., et al. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology 2007, 148:2690-2697.
23. Li L., Yang G., Li Q., Tang Y., Yang M., Yang H. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006, 114:544-548.
24. Soriguer F., Garrido-Sanchez L., Garcia-Serrano S., Garcia-Almeida J.M., Garcia-Arnes J., Tinahones F.J., et al. Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus. Obes Surg 2009, 19:1574-1580.
25. Lv D., Li H., Chen L. Apelin and APJ, a novel critical factor and therapeutic target for atherosclerosis. Acta Biochim Biophys Sin 2013, 45:527-533.
26. Chun H.J., Ali Z.A., Kojima Y., Kundu R.K., Sheikh A.Y., Agrawal R., et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008, 118:3343-3354.
27. Tao J., Zhu W., Li Y., Xin P., Li J., Liu M., et al. Apelin-13 protects the heart against ischemia-reperfusion injury through inhibition of ER-dependent apoptotic pathways in a time-dependent fashion. Am J Physiol Heart Circ Physiol 2011, 301:H1471-H1486.
28. Pisarenko O.I., Shulzhenko V.S., Pelogeikina Iu A., Studneva I.M., Kkhatri D.N., Bespalova Zh D. Effects of exogenous apelin-12 on functional and metabolic recovery of isolated rat heart after ischemia. Kardiologiia 2010, 50:44-49.
29. Simpkin J.C., Yellon D.M., Davidson S.M., Lim S.Y., Wynne A.M., Smith C.C. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol 2007, 102:518-528.
30. Zeng X.J., Zhang L.K., Wang H.X., Lu L.Q., Ma L.Q., Tang C.S. Apelin protects heart against ischemia/reperfusion injury in rat. Peptides 2009, 30:1144-1152.
31. Berry M.F., Pirolli T.J., Jayasankar V., Burdick J., Morine K.J., Gardner T.J., et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004, 110:II187-II193.
32. Ceylan-Isik A.F., Kandadi M.R., Xu X., Hua Y., Chicco A.J., Ren J. Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J Mol Cell Cardiol 2013, (this issue).
33. Borradaile N., Han X., Harp J., Gale S., Ory D., Schaffer J. Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J Lipid Res 2006, 47:2726-2737.
34. Young M., McNulty P., Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 2002, 105:1861-1870.
35. Dolinsky V.W., Dyck J.R. Role of AMP-activated protein kinase in healthy and diseased hearts. Am J Physiol Heart Circ Physiol 2006, 291:H2557-H2569.
36. Alonso-Galicia M., Brands M.W., Zappe D.H., Hall J.E. Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Hypertension 1996, 28:1047-1054.
37. Abel E.D. Myocardial insulin resistance and cardiac complications of diabetes. Curr Drug Targets Immune Endocr Metabol Disord 2005, 5:219-226.
38. Foldes G., Horkay F., Szokodi I., Vuolteenaho O., Ilves M., Lindstedt K.A., et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003, 308:480-485.
39. Barnes G.D., Alam S., Carter G., Pedersen C.M., Lee K.M., Hubbard T.J., et al. Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ Heart Fail 2013, 6:482-491.